HTG Molecular Diagnostics, Inc. (HTGMQ)
HTG Molecular Diagnostics, Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Tucson, AZ, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $221. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -339.2%. Its beta of 2.96 implies it has historically moved more than the broad market.
HTG Molecular Diagnostics, Inc. operates as a life sciences company, specializing in the realm of precision medicine. They furnish specialized instruments, consumable products, and software applications engineered to automate the processing of samples and characterize a variety of molecular targets. Among their portfolio of molecular profiling panels are offerings like the HTG Transcriptome Panel, HTG EdgeSeq precision immuno-oncology panel, HTG EdgeSeq miRNA whole-transcriptome assay, HTG EdgeSeq DLBCL cell of origin assay EU, HTG EdgeSeq Oncology Biomarker Panel, HTG immune response panel, and the HTG mouse mRNA tumor response panel. The company handles direct distribution of its instruments and consumables across the United States and Europe, supplementing this with a network of distributors for other parts of Europe and global markets. Its customer base primarily includes biopharmaceutical corporations, academic research institutions, and molecular testing laboratories. Incorporated in 1997 and based in Tucson, Arizona, the entity was formerly known as HTG, Inc., adopting its current name, HTG Molecular Diagnostics, Inc., in March 2011. However, on June 5, 2023, HTG Molecular Diagnostics, Inc. initiated a voluntary Chapter 11 reorganization filing with the U.S. Bankruptcy Court for the District of Delaware.
HTG Molecular Diagnostics, Inc. is most often compared with the following Healthcare names: